We expect the primary impact of the reclassification for consumers will be a greater level of quality for Active Medical Devices in terms of reliability, safety and effectiveness. By putting these medical devices into a higher class they will undergo more rigorous assessment prior to becoming...Read more
About Policy Submissions
We regularly make submissions to national level inquiries. If you are after a submission from earlier than listed here, please contact us.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation has been formed with a patient-centred approach in mind.
CHF notes that this consultation’s scope is limited to the regulatory guidance in line with existing regulatory requirements, and not...Read more
CHF appreciates the opportunity to provide a comment in response to proposed changes to a number of definitions and the scope of the medical device regulatory framework in Australia.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation...Read more
This submission is prepared in the context of an imminent federal election. CHF will be putting out an election priorities document which sets out our proposed agenda for health reform for through to 2025.Read more
CHF is committed to the National Medicines Policy and in ensuring that all Australians have access to high quality, safe medicines and that all medicines should be used in line with the principles of the quality use of medicines.
CHF is keen to ensure the scheduling process is used to...Read more
CHF welcomed the Review of Medicines and Medical Device Regulation. Whilst we did not support all the recommended approach of removing the required pre-approval of therapeutic goods advertisements to a complaints-based system, we are pleased to work with the Therapeutic Goods Administration (TGA...Read more
CHF applauds the PSA’s renewed commitment to quality, safety, and meeting evolving community needs. We support the PSA’s intention to expand pharmacist roles but feel that this discussion paper has focused too much on community pharmacists and has overlooked the possibilities for hospital and...Read more
The Australian Medical Research Advisory Board sought reflections and feedback on the first set of priorities for the Medical Research Future Fund (the MRFF) via a survey. This submission details CHF’s responses to the key questions in the survey.Read more
Our focus in this response is health data, as that is our area of expertise and interest. As recognised in the issues paper, health data is more sensitive than data about most other areas of a consumers’ lives, such as personal preference for transport to work or even more sensitive data like...Read more
CHF welcomed the Review of Medicines and Medical Device Regulation and, while we did not support removing the required pre-approval of therapeutic goods advertisements, we are pleased to work with the Therapeutic Goods Administration (TGA) to ensure that new arrangements will continue to protect...Read more